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a b s t r a c t
Background and purpose: Linear quadratic models predict that hypofractionation increases the biological
effect of physical dose inhomogeneity. The clinical signiﬁcance of this effect was tested retrospectively in
a trial of adjuvant breast hypofractionation.
Methods: The UK FAST trial randomised 915 women after breast conservation surgery between standard
fractionation and two dose levels of a 5-fraction regimen delivering 5.7 or 6.0 Gy fractions in 5 weeks,
using 3D dosimetry. Logistic regression tested for association between the absolute volumes receiving
different isodose level >100% of prescribed dose (hotspots) and the risk of change in 2-year photographic
breast appearance. The strength of this association was compared between control and hypofractionated
groups.
Results: Three hundred and ninety datasets from 11 participating centres were available for analysis. At
2 years post-randomisation, 81 (20.8%) had mild change and 24 (6.2%) had marked change in photo-
graphic breast appearance. After adjusting for breast size and surgical deﬁcit, there was no statistically
signiﬁcant association between the risk of 2-year change in breast appearance and dose inhomogeneity
in either the control or hypofractionated schedules, according to the various deﬁnitions of hotspots
analysed. The magnitude of the effect of dosimetry on 2-year change in breast appearance did not vary
signiﬁcantly between control and hypofractionated schedules for any of the dosimetry parameters
(p > 0.05 for all heterogeneity tests).
Conclusion: Dose inhomogeneity had no greater impact on the risk of 2-year change in photographic
breast appearance after hypofractionated breast radiotherapy than after standard fractionation.
 2012 Elsevier Ireland Ltd. All rights reserved. Radiotherapy and Oncology 104 (2012) 143–147
The routine use of hypofractionation in breast radiotherapy is
supported by outcome data of four large randomised clinical trials
in womenwith early breast cancer [1–7]. Residual concerns include
the impact of dose inhomogeneity on the risk of adverse
effects after hypofractionated schedules, so-called ‘treble trouble’
[8–10]. A causal association between breast dose inhomogeneity
and the risk of late tissue complications is suggested by the 5 years
follow up results of a UK randomised trial (N = 306) comparing 2D
versus 3D breast dosimetry [11]. Assuming dose distribution mat-
ters, it is not known if residual dose inhomogeneity in patients trea-
ted using 3D dose compensation contributes to a higher risk of
adverse effects after hypofractionated radiotherapy than after stan-
dard regimens. Against this background, a retrospective analysis of
a UK hypofractionation trial, which recently published its 2 years
follow-up results [12], has been undertaken to test the hypothesis
that residual dose inhomogeneity has a greater impact on late ad-
verse effect in women prescribed hypofractionated whole breast
radiotherapy, even when delivered in conformity with the Interna-
tional Commission on Radiation Units and Measurements (ICRU)
[13,14].
Methods
FAST trial study population
Between 2004 and 2007, 915 patients participated in the UK
FAST trial, a prospective randomised clinical trial of adjuvant whole
breast radiotherapy testing 5 once-weekly fractions of 6.0 Gy (test
group 1, iso-effective with control if a/b = 4 Gy) and 5.7 Gy (test
group 2, iso-effective with control if a/b = 3 Gy) against a control
arm of 25 fractions of 2.0 Gy in terms of late normal tissue effects
after local excision of early breast cancer [12]. The trial eligibility
criteria included (i) age not younger than 50 years old, (ii) invasive
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carcinoma breast, (iii) pathological tumour size smaller than 3 cm,
(iv) complete microscopic resection with negative axillary node.
The exclusion criteria were patients who required (i) mastectomy,
(ii) lymphatic radiotherapy, (iii) radiotherapy breast boost and
(iv) neoadjuvant or adjuvant cytotoxic therapy. Patients were ran-
domised (1:1:1) between the three trial arms.
Deﬁnition and assessment of late adverse radiation effects in the FAST
trial
The primary endpoint of the FAST trial was late radiation-in-
duced changes in breast appearance scored on a graded 3-point
scale (none, mild or marked change) from serial photographs
scored by three observers blind to treatment allocation [15] at 2
and 5 years post-radiotherapy compared to post-surgical baseline
photographs. The START trial conﬁrmed year 2 to be a valid time
point for assessment, given a strong correlation between photo-
graphic scores at years 2 and 5 [1]. FAST trial recruitment was com-
pleted in March 2007, so 5-year assessments were unavailable for
this analysis.
Radiotherapy technique
All patients were treated in a supine position with the help of
immobilisation devices such as a breast board. The radiotherapy
plan consisted of two standard tangential ﬁelds with non-divergent
posterior ﬁeld edges. The dose was prescribed to the standardised
prescription point deﬁned in the Standardisation of Breast Radio-
therapy (START) Trial [16], half-way between the lung surface and
the skin surface on the perpendicular bisector of the posterior treat-
ment beam edge. The FAST protocol followed the ICRU reports 50
and 62 guidelines, recommending variation of dose throughout
the treated volume to lie between 5% to +7% of prescribed dose.
This was achieved using three dimensional (3D) dose compensation
methods to ensure a maximum dose (Dmax) <107% of the pre-
scribed dose. By ICRU deﬁnitions, Dmax is the maximum dose
received by a sphere volume with a diameter >15 mm. For this
study, Dmax was deﬁned as the maximum dose to a volume >2 cc
[13,14].
The majority of patients were treated with simple forward
planned multi-leaf collimator (MLC) segment ﬁelds/Field in Field
(FIF) technique and the rest of them were treated using physical
breast compensators or inverse planned MLC segment ﬁelds.
Dosimetry data collection and analysis
The majority of commercial planning systems were capable of
export either in RTOG or DICOMRT format. When exported in this
way, data sent to the quality assurance (QA) team included plan-
ning computed tomography (CT) scans, treatment plan parameters,
details of structures outlined and the radiation dose within the
treatment volume computed by the planning system. Although
the FAST trial protocol encouraged participating centres to use full
CT planning, it was not a compulsory trial entry requirement. This
study only used plans with a complete CT set in order to ensure
accurate estimation of absolute breast volumes. As it was not a
mandatory requirement to outline the breast, analysis was per-
formed by exporting the whole dose cube of a patient’s plan to ob-
tain the whole patient volume’s dose volume histogram (DVH). For
conventional breast radiotherapy treatment utilising a tangential
pair with non-divergent posterior beam edges, the cumulative
treatment volumes receiving 50% of the prescribed dose were used
to represent the whole breast treatment volume. The limitation of
using this treatment volume surrogate is the inclusion of lung and
heart volumes within the 50% isodose, although this effect should
be minimised by the trial’s recommendations of maximum lung
distance and maximum heart distance in the treatment volume
to be less than 2 and 1 cm, respectively [17].
In order to investigate the dose heterogeneity effect on late tis-
sue complications, this study used the cumulative breast volumes
receiving more than the prescribed dose as the deﬁnitions of ‘‘hot-
spots’’. Absolute volumes of breast tissues exposed to P50%,
P100%, P103%, P105% and P107% of the prescribed dose were
recorded.
Statistical methods
The absolute breast volumes receiving P100%, P103%, P105%
and P107% of the prescribed dose were summarised using the
medians and the inter-quartile ranges (IQRs). Medians were cho-
sen instead of means as the distributions were highly skewed. As
very few patients had marked change in breast appearance, the
mild and marked change categories were combined to deﬁne the
endpoint of any change in photographic breast appearance at
2 years versus none.
For each dose zone, medians were used to split the distribution
into two groups for the analysis: <median and Pmedian. As
Table 1
Patient characteristics of this study sample (n = 390) compared with overall
distribution in FAST Trial (n = 915).
Distribution in study
sample, n (%)
Overall distribution in
FAST Trial (%)
Age (years)
50–59 138 (35) 36
60–69 184 (47) 48
70–79 61 (16) 14
80– 7 (2) 2
Mean (SD) [range] 63.2 (7.5) [50–88] 62.9 (7.2) [50–88]
Time from surgery to randomisation (weeks)
Median (interquartile
range) [range]
5.4 (4.1–6.7) [1.4–21.1] 5.8 (4.3–7.4) [0.4–22.1]
Histological type
Ductal 298 (76) 74
Lobular 32 (8) 10
Other 60 (16) 16
Axillary surgery
Sampling 207 (53) 44
Clearance 67 (17) 27
SNBa with or without
sampling
102 (26) 25
Other 14 (4) 4
Pathological tumour size (cm)
<1 121 (31) 28
1- 200 (51) 54
2- 69 (18) 18
Mean (SD) [range] 1.3 (0.6) [0.05–6.0] 1.4 (0.7) [0.05–11.4]
Tumour grade
1 138 (35) 34
2 212 (54) 55
3 38 (10) 11
Unknown 2 (1) 0
Adjuvant systemic therapy
Yes 345 (88) 88
No 45 (12) 12
Breast sizeb
Small 210 (54) 57
Medium 144 (37) 32
Large 36 (9) 11
Surgical deﬁcitb
Small 215 (55) 54
Medium 111 (29) 27
Large 64 (16) 20
a SNB = sentinel node biopsy.
b Assessed from baseline photographs.
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Fig. 1. Distribution of absolute breast volume receiving P100% of prescribed dose in patients with none versus mild/marked change in photographic breast appearance at
2 years.
Table 2
Results of logistic regression analyses testing association between breast volume receiving different levels of prescribed dose (using different deﬁnitions of hotspots) and risk of
adverse change in 2-year photographic breast appearance, separately for control and hypofractionated treatment schedules.
Control schedule Hypofractionated schedules
Mild/marked change in breast
appearance at 2 years/total (%)
Adjusted ORb
(95%CI), p-
value
Mild/marked change in breast
appearance at 2 years/total (%)
Adjusted OR2
(95%CI), p-
value
Test for heterogeneity between
treatment schedules, p-value
Breast volume receiving
P100% dose,cc1
p = 0.17 p = 0.09 p = 0.63
<529 6/60 (10.0) 1 29/135 (19.1) 1
P529 19/71 (26.8) 2.19 (0.71–
6.78)
51/124 (41.1) 1.70 (0.93–
3.13)
Breast volume
receivingP 103%
dose,cc1
p = 0.42 p = 0.86 p = 0.39
<112 8/62 (12.9) 1 35/133 (26.3) 1
P112 17/69 (24.6) 1.52 (0.55–
4.21)
45/126 (35.7) 0.95 (0.52–
1.72)
Breast volume receiving
P105% dose, cc1
p = 0.07 p = 0.29 p = 0.29
<12 8/69 (11.6) 1 32/130 (24.6) 1
P12 17/62 (27.4) 2.56 (0.93–
7.02)
48/129 (37.2) 1.36 (0.77–
2.41)
Any breast volume
receiving P107%
dose?
p = 0.92 p = 0.63 p = 0.91
No 16/88 (18.2) 1 48/164 (29.3) 1
Yes 9/43 (20.9) 1.05 (0.40–
2.80)
32/95 (33.7) 1.15 (0.65–
2.02)
OR = odds ratio.
CI = conﬁdence interval.
a Medians used to deﬁne categories.
b Adjusted for breast size and surgical deﬁcit.
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absolute breast volumes receivingP107% of prescribed dose were
very small, a variable indicating whether or not any volume re-
ceived P107% dose was used for the analysis instead.
Due to small numbers of patients with change in breast appear-
ance in some categories, the two hypofractionated schedules were
grouped together for the analysis and comparisons were made
between the control group (50 Gy in 25 fractions) and a combined
hypofractionated treatment group (30 Gy in ﬁve fractions and
28.5 Gy in ﬁve fractions). Multiple logistic regression was used to
test the association between breast volume receiving different
levels of prescribed dose and risk of adverse change in 2-year pho-
tographic breast appearance, separately for control and hypofrac-
tionated treatment schedules, and adjusting for breast size and
surgical deﬁcit (each assessed by a team of three observers as small,
medium or large from baseline photographs taken post-surgery but
pre-radiotherapy) as these were signiﬁcant risk factors for adverse
effects in this dataset. Finally, the test of heterogeneity was used to
compare the effect of dose heterogeneity on changes in breast
appearance between the two treatment schedules by ﬁtting an
interaction between dose heterogeneity and treatment in the mul-
tiple logistic regression model.
Results
Nine hundred and ﬁfteen patients were recruited from 18 UK
radiotherapy centres into the FAST trial between 2004 and 2007.
Treatment plans were available in DICOMRT or RTOG electronic
formats with full CT planning for 469 patients (51.2% of 915) from
11 centres, and of these, 390 (83.1% of 469) had a score for change
in photographic breast appearance at 2 years available, forming the
dataset for analysis in this study. Reasons for the 2-year photo-
graphic score being unavailable were breast reconstruction (1),
recurrence or second primary (3), died (4), emigrated or moved
(3), no baseline photograph (17), patient not seen at 2 years (6),
2-year photograph not taken (3), patient withdrew from photo-
graphic study (4) and reason unknown (38).
There was no signiﬁcant difference between the control and
hypofractionated treatment groups in terms of median breast vol-
umes receiving P50% isodose (1496 cc for control and 1386 cc for
hypofractionated, p = 0.56 > 0.05). Table 1 summarises the patient
tumour and treatment characteristics of the study sample, showing
them to be representative of the FAST trial population as a whole
(n = 915). Age, time between surgery and randomisation, histolog-
ical type, pathological tumour size, and tumour grade were compa-
rable between the sample and the total FAST population.
At 2 years post-randomisation, 285 (73.1%) women had no
change in photographic breast appearance, 81 (20.8%) had mild
change and 24 (6.2%) had marked change. The median breast vol-
ume (IQR) for each isodose group P100%, P103%, P105% and
P107% were 529 cc (335–783), 112 cc (57–210), 12 cc (3–31)
and 0 cc (0–0.1) respectively. One hundred and thirty eight out of
390 patients (35.4%) had a volume receiving more than 107% of
the prescribed dose, although the absolute volumes were very
small. Fig. 1 shows the overlap between the distributions of breast
volumes receiving P100% of the dose for patients who had none
versus any change in photographic breast appearance at 2 years.
Results from the multiple logistic regression analyses are shown
in Table 2, and suggested that after adjusting for breast size and
surgical deﬁcit, there was no evidence that the risk of late adverse
effects of radiotherapy was associated with dose inhomogeneity
according to the various deﬁnitions of hotspots analysed. As shown
by the results of the tests for heterogeneity and the overlapping
95% conﬁdence intervals for the odds ratios, the effect of residual
dose inhomogeneity of whole breast treatment with 3D dose com-
pensations on adverse effects did not vary signiﬁcantly between
the control and hypofractionated schedules, for any of the dosim-
etry parameters (p > 0.05 for all heterogeneity tests).
Discussion
This study aimed to investigate the impact of dose inhomogene-
ity on late adverse effects when hypofractionated schedules are
introduced, since partial volumes absorbing >100% of prescribed
dose suffer an increase in both total dose and dose per fraction,
so-called double trouble [18]. Based on the linear-quadratic (LQ)
formulation, hot spots are penalised more severely in a hypofrac-
tionated treatment, the so-called treble trouble effect [18,19]. In
theory, the clinical effect is expected to be very small, but there
is a lingering concern that it might matter in practice, especially
if dosimetry is suboptimal. Due to the size and shape of the target
volume encompassed in whole breast radiotherapy, there is great-
er dose heterogeneity than other tumour sites, with up to 28% dose
heterogeneity using conventional 2-dimensional planning [20].
Recent ASTRO guidelines for hypofractionated whole breast radio-
therapy recommend the use of three-dimensional dose compensa-
tion to optimise dose homogeneity when breast hypofractionation
is used, although this measure is beneﬁcial with conventional frac-
tionation too [21]. Five fractions of 5.7 Gy, as tested in the FAST
trial for example, are iso-effective with 50 Gy in 25 fractions at
the 100% reference point, assuming a/b = 3 Gy [12]. Partial volumes
receiving 105% of this prescribed dose absorb an equivalent total
dose expressed in 2.0 Gy fractions of 54.3 Gy after ﬁve fractions
of 5.7 Gy compared to 53.5 Gy after 25 fractions of 2.0 Gy. This
dose difference encompassing the whole breast would be clinically
signiﬁcant, but delivered to partial volumes comprising a few per-
cent of whole breast are not relevant. In the present study, all par-
ticipating centres achieved the requirement, as indicated by
median (IQR) volumes of 105% and 107% hotspots of 12 cc (3–31)
and 0 cc (0–0.1), respectively. The study detected no excess risk
of adverse effects attributable to hotspots in the hypofractionated
treatment schedules (5.7 or 6.0 Gy per fraction) compared with
hotspots in the conventional 2 Gy treatment schedule. In other
words, there was no evidence for a treble trouble effect in the FAST
patient dataset.
Only 40% of the FAST trial sample population were used in this
analysis due to limitations in the central collection of 3D dosimetry
datasets, but there is no evidence to suggest that the patients in-
cluded in this study are unrepresentative the FAST trial population.
Change in photographic breast appearance at 2 years was used to
deﬁne the late adverse effect caused by radiotherapy in this study.
This endpoint has been well established and validated in random-
ised clinical trials, indicating it to be sensitive to small (<10%)
differences in randomised total dose [1–3,7,11]. The 2-year time-
point is predictive of the relative effects of randomised groups at
longer follow up, even though the absolute rate of adverse effects
continues to rise for at least a decade and probably for life
[7,22,23]. The limiting factor is not, therefore, the 2-year time-
point, but the total number of adverse events available for analysis,
and particularly when stratiﬁed by treatment schedule. Although
the statistical power to adequately test formally for heterogeneity
is low, based on 105 adverse events recorded in 390 patients, the
95% conﬁdence intervals on the odds ratios for hypofractionated
treatments according to size of partial volumes receiving >100%
prescribed dose are narrow enough to reassure.
Conclusion
Assuming ICRU limits on dosimetry can be met, there is no evi-
dence that the adoption of hypofractionation enhances the adverse
impact of residual dose inhomogeneity on the risk of late adverse
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effects of radiation recorded by change in photographic breast
appearance.
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